Skip to main content
. 2015 Oct 12;6(34):36587–36602. doi: 10.18632/oncotarget.5500

Figure 3. Novel fusion between DHX35 and BPIFA2 is in concordance with 3′ overexpression of BPIFA2.

Figure 3

A. The exon expression profile of BPIFA2 shows that one CRC sample has a 3-fold increase in expression of the 3′ part of the gene compared to the median of the cohort. The last four probe sets showed increased intensity levels and target exon 7, 8 and 9 of BPIFA2. B. Normalized read counts mapping to DHX35 were high only in sample16_T, the same sample which exhibits increased 3′ expression of BPIFA2. C. From RACE-seq we identified a fusion between exon 11 of DHX35 and exon 7 of BPIFA2. Exons 1–11 of DHX35 show high read coverage, measured in RPK. Exons 12–22, located downstream of the breakpoint in DHX35, were not covered by any reads, indicating that the RACE assay that targets BPIFA2 specifically amplifies the upstream DHX35 part of the fusion. By realigning sequencing reads from the sample in question to a fusion scaffold, we found that 207 unique split reads align across the fusion boundary.